Core Laboratories NV (CLB) Now Covered by Loop Capital
Investment analysts at Loop Capital initiated coverage on shares of Core Laboratories NV (NYSE:CLB) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the stock.
A number of other equities research analysts have also weighed in on CLB. Zacks Investment Research lowered shares of Core Laboratories NV from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 26th. Citigroup Inc. lowered their target price on shares of Core Laboratories NV from $123.00 to $118.00 and set a “neutral” rating on the stock in a report on Monday, July 25th. KLR Group restated a “buy” rating and issued a $180.00 target price (up previously from $166.00) on shares of Core Laboratories NV in a report on Monday, June 13th. Credit Suisse Group AG began coverage on shares of Core Laboratories NV in a report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Core Laboratories NV in a report on Friday, June 10th. They issued an “overweight” rating and a $120.00 target price on the stock. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Core Laboratories NV presently has an average rating of “Hold” and an average target price of $119.76.
Shares of Core Laboratories NV (NYSE:CLB) opened at 110.48 on Friday. The firm has a market capitalization of $4.87 billion, a P/E ratio of 58.61 and a beta of 1.56. The stock has a 50 day moving average of $112.06 and a 200-day moving average of $117.51. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49.
Core Laboratories NV (NYSE:CLB) last posted its earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.35. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The company had revenue of $148.10 million for the quarter, compared to analyst estimates of $146.37 million. During the same quarter in the prior year, the business posted $0.81 EPS. The firm’s revenue was down 27.4% compared to the same quarter last year. Equities analysts expect that Core Laboratories NV will post $1.55 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLB. Balentine LLC increased its position in Core Laboratories NV by 44.3% in the second quarter. Balentine LLC now owns 893 shares of the company’s stock worth $111,000 after buying an additional 274 shares in the last quarter. MU Investments Co. Ltd. bought a new position in Core Laboratories NV during the second quarter worth $115,000. Pinkerton Retirement Specialists LLC bought a new position in Core Laboratories NV during the second quarter worth $127,000. Fifth Third Bancorp increased its position in Core Laboratories NV by 15.3% in the second quarter. Fifth Third Bancorp now owns 1,166 shares of the company’s stock worth $144,000 after buying an additional 155 shares in the last quarter. Finally, AXA increased its position in Core Laboratories NV by 94.2% in the second quarter. AXA now owns 1,400 shares of the company’s stock worth $173,000 after buying an additional 679 shares in the last quarter.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Stock Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related stocks with our FREE daily email newsletter.